New Brunswick Scientific to Introduce Five Innovative New Products at the American Society for Microbiology (ASM) General Meetin

New Brunswick Scientific to Introduce Five Innovative New
Products at the American Society for Microbiology (ASM) General Meeting 


EDISON, N.J., May 27  /PRNewswire-FirstCall/ -- New Brunswick Scientific Co.,
Inc. (NBS) (NASDAQ:NBSC), yesterday announced that it will be introducing five
innovative new products at the American Society for Microbiology (ASM) General
Meeting, which opens on June 6th in Atlanta, GA. The announcement by James
Orcutt, NBS President and COO, was made during an open question and answer
forum at the Company's annual shareholders' meeting.

The products were identified as two new biological shakers, Innova(R) 40, a
benchtop incubated and refrigerated system; and Innova 43, a larger-scale floor
model. Innova shakers are the workhorses of the industry, known for precision
control of operating parameters and exceptionally long life. With this latest
complement to its shaker family, the Company now offers over 30 shaker models
-- the largest selection offered by any manufacturer -- providing life
scientists with a range of options to suit virtually any culture requirement.

A new slim upright, 360 liter capacity, ultra-low temperature freezer, Innova
U360, will also be introduced. This latest freezer in the Innova family
utilizes vacuum-insulation panel technology in place of traditional insulating
foam. Vacuum-insulation panels reduce wall thickness, thereby maintaining a
small footprint while increasing interior storage capacity. With the addition
of the Innova U360, the Company now offers ten freezer models, including a
unique personal-sized unit for on- or under-bench use.

Mr. Orcutt also announced plans to introduce a new 500 mL disposable cell
culture system. FibraStage(TM), the first truly disposable product in NBS'
product range, offers the simplicity of operation and convenience of disposable
technology, while providing higher yields than typically achieved using
traditional culture systems, such as spinners, T-flasks and roller bottles. He
went on to explain that the Company's proprietary FibraCel(R) disks, which are
at the heart of the FibraStage system, are currently being used to produce the
world's first licensed gene therapy drug.

Rounding out the new product introductions is the NucleoCounter YC-100, a
device for more accurately and automatically counting yeast cells. The YC-100
serves as a counterpoint to the original NucleoCounter, which automates the
tedious task of counting mammalian cells. Mr. Orcutt commented that
"accelerated and targeted new product development is among several strategic
initiatives upon which NBS is focused. With the introduction of these products
at ASM, the results of this sustained effort are beginning to show."

To be added to New Brunswick Scientific's e-mail distribution list, please
click on the link below:
http://www.clearperspectivegroup.com/clearsite/nbsc/emailoptin.html

About New Brunswick Scientific

New Brunswick Scientific Co., Inc., is a leading global provider of a
comprehensive line of research equipment and scientific instrumentation for use
in the life science industry. The Company's products are used in the creation,
maintenance and control of physical and biochemical environments required for
the growth, detection and storage of microorganisms for medical, biological and
chemical applications, as well as environmental research and commercial product
development. NBS is a forerunner in the research and development of pioneering
equipment to meet the challenges of new areas of advancement in life science.
Established in 1946, New Brunswick Scientific is headquartered in Edison, New
Jersey, with sales and distribution facilities strategically located in the
United States, Europe and Asia. For more information, please visit
http://www.nbsc.com/ .

This document contains "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995.  Forward-looking statements
may be identified by words such as "expects," "anticipates," "intends,"
"plans," "believes," "seeks," "estimates," "will" or words of similar meaning
and include, but are not limited to, statements about the expected future
business and financial performance of the Company. The forward-looking
statements involve a number of risks and uncertainties, including but not
limited to, changes in economic conditions, demand for the Company's products,
pricing pressures, intense competition in the industries in which the Company
operates, the need for the Company to keep pace with technological developments
and respond in a timely manner to changes in customer needs, the Company's
dependence on third-party suppliers, the effect on foreign sales of currency
fluctuations, acceptance of new products, the labor relations of the Company
and its customers and other factors identified in the Company's Securities and
Exchange Commission filings. Forward-looking statements are based on
management's current expectations and assumptions, which are inherently subject
to uncertainties, risks and changes in circumstances that are difficult to
predict. Actual outcomes and results may differ materially from these
expectations and assumptions due to changes in global political, economic,
business, competitive, market, regulatory and other factors. The Company
undertakes no obligation to publicly update or review any forward-looking
information, whether as a result of new information, future developments or
otherwise. 

DATASOURCE: New Brunswick Scientific Co., Inc.



CONTACT:  Samuel Eichenbaum, Vice President, Finance and Treasurer,

New Brunswick Scientific Co., Inc., [phone], ; Matthew J.

Dennis, CFA, NBS Investor Relations, Clear Perspective Group, LLC,

[phone], , for New Brunswick Scientific Co., Inc.



Web site:  http://www.nbsc.com/ 

Copyright